Additions and Corrections pubs.acs.org/crystal
Correction to Crystal Engineering with the Uranyl Cation III. Mixed Aliphatic Dicarboxylate/Aromatic Dipyridyl Coordination Polymers: Synthesis, Structures, and Speciation Andrew T. Kerr and Christopher L. Cahill* Cryst. Growth Des. 2011, 11 (12), 5634−5641. DOI: 10.1021/cg2011869
T
he original paper contained typographical errors in Table 1 and incorrect cell parameters in Table 2. Below are the corrected tables. Table 1. Synthesis Conditions for Compounds 1−7 compound empirical formula aliphatic dicarboxylate dipyridyl pH (init./final) topology secondary building unit pure? role of dipyridyl
1
2
3
4
5
6
7
C32H46N2O13U2 sebacic acid
C27H52N2O39U6 glutaric acid
C36H48N2O16U2 suberic acid
C48H60N4O26U5 suberic acid
C30H38N2O12U2 azelaic acid
C22H28N2O10U2 sebacic acid
C39H58N2O18U2 azelaic acid
BPE 4.95/4.91 3D monomers
BPE′ 3.55/4.27 2D sheets edge sharing chains no charge balancing
BPE′ 4.83/3.85 2D anionic chains monomers
BPE′ 4.86/4.83 3D monomers and tetramers no direct coordination
BPE′ 2.14/4.02 2D sheets monomers
BPE′ 7.09/5.67 2D sheets point sharing chains no direct coordination
BPE′ 3.63/3.46 2D anionic chains monomers
yes direct coordination
no charge balancing
no direct coordination
no charge balancing
Table 2. Crystallographic Data for Compounds 1−7 compound
1
2
3
4
5
6
7
empirical formula formula weight crystal system space group a (Å) b (Å) c (Å) α (deg) β (deg) γ (deg) V (Å3) temp (K) Z λ (Mo Kα) Dcalc (g cm−3) μ (mm−1) Rint R1 [I> 2σ(I)] wR2 [I> 2σ(I)]
C32H46N2O13U2 2285.54 monoclinic C2 20.5890(15) 20.5391(15) 10.4699(8) 90 118.4780(10) 90 3891.8(5) 298 4 0.71073 1.950 8.372 0.0964 0.0361 0.0871
C36H48N2O16U2 2462.93 orthorhombic C2221 12.534(2) 16.139(3) 25.294(4) 90 90 90 5116.6(15) 298 4 0.71073 3.197 19.031 0.1327 0.0522 0.1216
C36H47N2O16U2 1239.58 monoclinic P21/n 8.9327(5) 19.2047(11) 11.8920(7) 90 94.4790(10) 90 2033.8(2) 298 4 0.71073 2.026 8.025 0.0390 0.0220 0.0418
C48H60N4O26U5 2299.45 triclinic P1̅ 9.6535(9) 9.7736(9) 17.4401(17) 87.842(2) 75.9440(10) 70.2170(10) 1500.2(2) 298 1 0.71073 2.545 13.532 0.0215 0.0191 0.0423
C30H38N2O12U2 1094.58 triclinic P1̅ 8.1535(3) 9.4052(3) 12.3338(4) 108.60(1) 96.0540(10) 100.7710(10) 866.67(5) 100 2 0.71073 2.097 9.392 0.0181 0.0199 0.0414
C22H28N2O10U2 956.58 monoclinic P21/n 9.4706(4) 8.3098(3) 17.9773(6) 90 113.185(2) 90 1300.53(9) 100 4 0.71073 2.437 12.492 0.0484 0.0174 0.0428
C39H58N2O18U2 1318.93 monoclinic C2/c 25.4837(8) 15.9313(5) 25.4808(11) 90 118.76(2) 90 9068.4(6) 100 8 0.71073 1.932 4.208 0.0478 0.0263 0.0556
© XXXX American Chemical Society
A
DOI: 10.1021/acs.cgd.5b00703 Cryst. Growth Des. XXXX, XXX, XXX−XXX
